Literature DB >> 36128478

A Call for Implementation Science: Achieving Equitable Access to SGLT2 Inhibitors.

Sophie E Claudel1, Insa M Schmidt2, Ashish Verma2.   

Abstract

Entities:  

Keywords:  SGLT2i; chronic kidney disease; diabetes; diabetes and the kidney; disparity; equity; implementation science; sodium-glucose transporter 2 inhibitors

Mesh：

Substances：

Year:  2022        PMID： 36128478      PMCID： PMC9438421          DOI： 10.34067/KID.0001512022

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  10 in total

Review 1.  The Global Epidemiology of Diabetes and Kidney Disease.

Authors:  Digsu N Koye; Dianna J Magliano; Robert G Nelson; Meda E Pavkov
Journal:  Adv Chronic Kidney Dis       Date:  2018-03       Impact factor: 3.620

2.  Effectiveness of using STOPP/START criteria to identify potentially inappropriate medication in people aged ≥ 65 years with chronic kidney disease: a randomized clinical trial.

Authors:  Krystina Parker; Ingrid Bull-Engelstad; Jūratė Šaltytė Benth; Willy Aasebø; Nanna von der Lippe; Morten Reier-Nilsen; Ingrid Os; Knut Stavem
Journal:  Eur J Clin Pharmacol       Date:  2019-07-29       Impact factor: 2.953

3.  Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits.

Authors:  Yumin Gao; Eric Peterson; Neha Pagidipati
Journal:  Am Heart J       Date:  2020-03-20       Impact factor: 4.749

4.  Too Many for Too Few: Finding Appropriate Nephrology Referrals for Patients With CKD That Optimize Outcomes.

Authors:  Chi D Chu; Julio A Lamprea-Montealegre; Michelle M Estrella
Journal:  Am J Kidney Dis       Date:  2022-01-12       Impact factor: 8.860

5.  Real-Life Prescribing of SGLT2 Inhibitors: How to Handle the Other Medications, Including Glucose-Lowering Drugs and Diuretics.

Authors:  David Lam; Aisha Shaikh
Journal:  Kidney360       Date:  2021-02-01

6.  The Quintuple Aim for Health Care Improvement: A New Imperative to Advance Health Equity.

Authors:  Shantanu Nundy; Lisa A Cooper; Kedar S Mate
Journal:  JAMA       Date:  2022-02-08       Impact factor: 56.272

7.  A Pilot Study Embedding Clinical Pharmacists Within an Interprofessional Nephrology Clinic for the Initiation and Monitoring of Empagliflozin in Diabetic Kidney Disease.

Authors:  Laura K Triantafylidis; Chelsea E Hawley; Christopher Fagbote; Jiahua Li; Nicole Genovese; Julie M Paik
Journal:  J Pharm Pract       Date:  2019-09-24

8.  Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US.

Authors:  Lauren A Eberly; Lin Yang; Nwamaka D Eneanya; Utibe Essien; Howard Julien; Ashwin S Nathan; Sameed Ahmed M Khatana; Elias J Dayoub; Alexander C Fanaroff; Jay Giri; Peter W Groeneveld; Srinath Adusumalli
Journal:  JAMA Netw Open       Date:  2021-04-01

9.  CKD Awareness Among US Adults by Future Risk of Kidney Failure.

Authors:  Chi D Chu; Charles E McCulloch; Tanushree Banerjee; Meda E Pavkov; Nilka R Burrows; Brenda W Gillespie; Rajiv Saran; Michael G Shlipak; Neil R Powe; Delphine S Tuot
Journal:  Am J Kidney Dis       Date:  2020-04-15       Impact factor: 8.860

10.  Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program.

Authors:  Jing Luo; Robert Feldman; Scott D Rothenberger; Inmaculada Hernandez; Walid F Gellad
Journal:  JAMA Netw Open       Date:  2020-10-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.